Nice approves life-extending drug for patients with incurable breast cancer A drug that can give women suffering from incurable advanced breast cancer an extra 16 months of life has been approved for general use in the NHS in England after a price cut was negotiated with the manufacturer.
The decision by Nice, the National Institute for Health and Care Excellence, to give the green light for NHS doctors to use pertuzumab, sold under the brand name of Perjeta by the Swiss drug company Roche, was enthusiastically welcomed by breast cancer charities. The Guardian
No comments:
Post a Comment